DrugPatentWatch Database Preview
Doxazosin mesylate - Generic Drug Details
» See Plans and Pricing
What are the generic sources for doxazosin mesylate and what is the scope of freedom to operate?
Doxazosin mesylate
is the generic ingredient in three branded drugs marketed by Upjohn, Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Upsher Smith Labs, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for doxazosin mesylate. Twenty-seven suppliers are listed for this compound.
Summary for doxazosin mesylate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 17 |
| NDAs: | 19 |
| Drug Master File Entries: | 14 |
| Suppliers / Packagers: | 27 |
| Bulk Api Vendors: | 92 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,778 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for doxazosin mesylate |
| Drug Sales Revenues: | Drug sales revenues for doxazosin mesylate |
| DailyMed Link: | doxazosin mesylate at DailyMed |
Recent Clinical Trials for doxazosin mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | N/A |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| University of Minnesota - Clinical and Translational Science Institute | Phase 2 |
Pharmacology for doxazosin mesylate
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for doxazosin mesylate
Paragraph IV (Patent) Challenges for DOXAZOSIN MESYLATE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| CARDURA | TABLET;ORAL | doxazosin mesylate | 019668 |
US Patents and Regulatory Information for doxazosin mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075509-003 | Oct 19, 2000 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Pliva | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075750-003 | Jun 8, 2001 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Watson Labs Inc | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075426-001 | Oct 18, 2000 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for doxazosin mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upjohn | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | Start Trial | Start Trial |
| Upjohn | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-003 | Nov 2, 1990 | Start Trial | Start Trial |
| Upjohn | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-004 | Nov 2, 1990 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
